Marchetti C, Rosati A, De Felice F, et al. - Researchers sought to determine the number of neoadjuvant chemotherapy cycles required in patients with advanced ovarian cancer. They identified a cohort of AEOC patients with stage III-IV epithelial OC who underwent NACT followed by IDS and classified the patients in group A (≤ 4 cycles) and group B (> 4 cycles). Group A and group B included 140 and 70 patients, respectively. After the propensity score matching, no imbalances were identified in baseline characteristics. Findings suggest the possibility of achieving absence of residual tumor at surgery regardless of number of cycles. Independent prognostic factors included complete cytoreduction and BRCA status.